11:21 AM EDT, 07/31/2026 (MT Newswires) -- Regeneron Pharmaceuticals' ( REGN ) robust Q2 sales from key products and limited spend increases are expected to help ramp H2 margins, RBC Capital Markets said in a Thursday research report.

The company's collaboration with Sanofi (SNY) could become a "more leverageable asset" in advancing immunology and inflammation products if the companies continue to sound more communicative, analysts wrote.

A decent uptake of Eylea HD to treat retinal conditions during the quarter is a clear positive for the company, analysts said, adding that they now model Eylea franchise US sales of $3.9 billion in 2026.

The brokerage said it reiterated its sector perform rating on the stock and boosted its price target to $737 per share from $696.

Price: 736.42, Change: -1.92, Percent Change: -0.26